The combination product Hemosin K (Carbazochrome and Menadione) is a systemic hemostatic agent whose therapeutic benefit is centered on providing supportive benefit in two major areas: addressing symptoms related to weak small blood vessels and supporting the body's natural response to bleeding. Based on the therapeutic class of its component (Carbazochrome) as a systemic hemostatic, the medication is generally used in areas where additional symptomatic support against hemorrhage is needed.

What Hemosin K Treats: Main Uses and Benefits

Hemosin K is applied across domains where additional symptomatic support for bleeding is needed. The primary therapeutic domains for use include managing acute bleeding episodes (such as persistent epistaxis and internal hemorrhages), supporting care in post-procedural contexts (like following dental extractions or minor surgery), and addressing the symptomatic burden of chronic vascular fragility (manifesting as easy bruising).

“The medication may assist with maintaining functional stability by helping to manage the overall volume and duration of blood loss in sudden, distressing episodes.”

Benefits and Symptom Focus

This supportive treatment assists patients by managing symptoms related to heightened physiological activity and symptoms that interfere with daily functioning. It provides support that helps ease the overall symptom burden by contributing to timely bleeding control and assisting with managing the frequency of disruptive spontaneous bleeding manifestations. The use is considered relevant for patients with conditions characterized by periods of heightened symptoms of blood loss or vascular leakage.

Who Can and Cannot Use Hemosin K? (Official Eligibility Rules)

This section summarizes the official population eligibility and contraindication rules for Hemosin K (Carbazochrome and Menadione), based strictly on regulatory prescribing information.

Populations Absolutely Prohibited (Contraindications)

️ Populations Requiring Restricted or Conditional Use

Use is not recommended or requires extreme caution for the following populations, unless a physician determines the benefits clearly outweigh the risks:

• Pregnancy and Lactation: Use is restricted and generally not recommended due to insufficient human safety data.
• Severe Hepatic/Biliary Impairment: Caution is mandated due to the role of the liver in metabolizing the Menadione component.
• History of Thrombotic Events: Caution is advised due to the hemostatic and potential platelet-aggregating effects of Carbazochrome.

Adults are the primary population for use, provided no contraindications exist.

Interaction Map: Interactions with other medicines and products — official regulatory information for Hemosin K

Interaction Scope

Interaction Classifications (High-Level)

Resulting Interaction Structure

Official interaction statements:

• Co-administration with Anticoagulants (e.g., Warfarin) is restricted due to pharmacodynamic antagonism resulting in a decreased anticoagulant effect.
• The effect is antagonized by Fibrinolytic or Thrombolytic Agents, classifying this as a therapeutic conflict with potential for decreased therapeutic efficacy.
• Orlistat causes a pharmacokinetic interaction by reducing the absorption of the Menadione component, leading to reduced systemic exposure.

Connection to the overall interaction profile (2-4 sentences):

Regulatory documents define the product's profile by emphasizing pharmacodynamic antagonism with antithrombotic agents and a pharmacokinetic reduction in absorption from a gastrointestinal lipase inhibitor. The most stringent restrictions classify combinations with clotting inhibitors as contraindicated. The interaction profile requires that coagulation parameters be monitored when co-administered with substances that reduce absorption. Interaction relevance is also officially noted to be conditional on underlying hepatic function.

Activating the Core Coagulation Cascade

Hemosin K contains a Vitamin K component that functions as an essential cofactor for the liver enzyme gamma-glutamyl carboxylase (GGCX). This enzymatic activity is required to biochemically activate specific coagulation factors (II, VII, IX, X). By modifying these factors, the drug enables them to bind calcium, which is necessary for their assembly on cellular surfaces and subsequent acceleration of the entire clotting cascade. This core mechanism influences the synthesis of functionally active coagulation factors, contributing to the formation of a fibrin clot.

Stabilizing Microvascular Walls

The drug's second component, Carbazochrome, acts locally to modulate the walls of capillaries and small venules. It achieves this by decreasing capillary permeability and influencing the resilience and tone of the microvascular endothelium. This mechanistic action physically limits the leakage of blood and fluid from the smallest vessels, contributing to the regulation of microvascular blood egress.

Synergistic Hemostatic Effect

The overall effect of the drug involves a synergistic influence on hemostasis. The Vitamin K mechanism addresses the biochemical synthesis and activation of the systemic clotting machinery, while the Carbazochrome mechanism addresses the structural integrity of the peripheral blood vessels. The two mechanisms function together to influence the body’s overall hemostatic response.

How Hemosin K is Used: Official Administration Guidelines

Hemosin K is a combination systemic hemostatic agent whose official usage is defined by standard practices, specifying the approved delivery methods, dose ranges, and necessary administration procedures.

Approved Administration Routes

The medicine is supplied in forms suitable for systemic delivery, based on the requirements for enhanced bleeding control. Official instructions detail two primary routes of administration:

• Oral Administration: Provided as a tablet or capsule for ingestion.
• Parenteral Administration: Delivered as a sterile solution for injection via the intramuscular (IM), subcutaneous (SC), or intravenous (IV) routes. The SC route is often preferred for the Vitamin K component in non-urgent settings.

Standard Dosing and Frequency

Standard adult dosing is based on the amount of each active ingredient required to achieve the intended supportive action. Dosing often follows a course of short-term or intermittent use, which is governed by clinical assessment.

Key Procedural Instructions

For the injectable solution, especially when administered intravenously, technical documents specify careful procedural steps:

• IV Administration Rate: Intravenous injections must be delivered very slowly, with the rate officially not exceeding 1 mg per minute to adhere to the established constraints for the Vitamin K component.
• Dilution: IV injection solutions must be diluted with approved fluids and administered immediately following preparation; any unused portion must be discarded.

Research evidence / Overview of Studies for Hemosin K

Evidence for Use in Managing Post-Surgical Bleeding

The research base for measured blood loss in surgery primarily focuses on the Carbazochrome component of Hemosin K. Research examined its study design role as an adjunct to other standard therapies, such as anti-fibrinolytic medicines, particularly during major procedures like hip and knee replacements.

The studies conducted were mainly short-term Randomized Controlled Trials (RCTs) and systematic reviews. These trials monitored outcomes related to measured blood loss, specifically tracking the total volume of blood loss and the rate of blood transfusions required by patients immediately following the procedure.

Studies reported measurements of blood loss and tracked outcomes such as measured changes in blood cell levels. However, because the component was primarily studied as an add-on, the evidence provides limited insight into Carbazochrome's role when studied on its own. Long-term outcomes related to systemic stability are not well established by these studies.

Evidence for Exploring Prevention of Vitamin K Deficiency Bleeding (VKDB)

Evidence in Special Populations

Research has provided specific insight into the infant population, where the Menadione component was studied for the purpose of prophylaxis against VKDB. This involved tracking measurements of coagulation factors in both term and preterm neonates and infants.

For other special groups, such as older adults or patients with comorbid conditions, data for the use of the combined product are still emerging. The research conducted during surgical settings often included adults of various ages, but findings for distinct subgroups are uncertain and the sample sizes were limited.

How to Store and Dispose of Hemosin K?

Strict adherence to official storage and disposal requirements is mandatory to maintain the quality and integrity of Hemosin K (Carbazochrome and Menadione).

Mandatory Storage Conditions

Handling and Disposal Rules

Do not freeze the injectable solution. For the injectable form, use immediately after opening and discard any unused portion. Do not use the medicine after the expiration date.

Disposal: Unused or expired Hemosin K must not be discarded in household waste or flushed down the toilet. Return the product to a pharmaceutical take-back program or official collection point. Used sharps (needles, ampoules) must be placed in a designated sharps container.